Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821155 | 0.88 | — | — | |
| SCHEMBL6049913 | 0.85 | HCAR2 (0.59) | HCAR2TDP1TP53TSHREGLN1 | |
| SCHEMBL8459108 | 0.85 | HCAR2 (0.59) | HCAR2TDP1TP53TSHREGLN1 | |
| SCHEMBL9249489 | 0.85 | HCAR2 (0.59) | HCAR2TDP1TP53TSHREGLN1 | |
| Succinic Acid SCHEMBL356092 | 0.82 | TDP1 (0.41) | USP2ALDH1A1CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL12863645 | 0.78 | ALDH1A1 (0.51) | USP2ALDH1A1CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL304203 | 0.76 | TDP1 (0.54) | USP2ALDH1A1CYP3A4MAPTSMN1; SMN2 | |
| Maleic Acid SCHEMBL28273343 | 0.76 | ALDH1A1 (0.58) | ALDH1A1HCAR2LMNAHSD17B10TP53 | |
| SCHEMBL6049909 | 0.75 | HCAR2 (0.45) | USP2ALDH1A1CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL11050380 | 0.75 | HCAR2 (0.45) | USP2ALDH1A1CYP3A4MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211725-A1 | Pharmaceutical Composition Comprising Venetoclax | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2022-07-07 | — | — | US | claimed |
| WO-2020225738-A1 | PHARMACEUTICAL COMPOSITION COMPRISING VENETOCLAX | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2020-11-12 | — | — | WO | claimed |
| EP-1847257-B1 | Solid preparation comprising enteric solid dispersion | SHINETSU CHEMICAL CO (JP) | 2017-11-22 | — | — | EP | claimed |
| US-20140370091-A1 | Method for Producing Aqueous Enteric Coating Liquid, Solid Preparation, and Method for Producing Same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-12-18 | — | — | US | claimed |
| EP-2813218-A1 | Method for producing aqueous enteric coating liquid, solid preparation, and method for producing same | Shin-Etsu Chemical Co., Ltd. (JP) | 2014-12-17 | — | — | EP | claimed |
| US-20080038340-A1 | Solid dosage form of enteric solid dispersion and method for producing the same | SHIN-ETSU CHEMICAL CO., LTD. | 2008-02-14 | — | — | US | claimed |
| EP-1886673-A2 | Solid dosage form of enteric solid dispersion and method for producing the same | Shin-Etsu Chemical Co., Ltd. (JP) | 2008-02-13 | — | — | EP | claimed |
| US-20070248682-A1 | SOLID PREPARATION COMPRISING ENTERIC SOLID DISPERSION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | claimed |
| EP-1847257-A2 | Solid preparation comprising enteric solid dispersion | Shin-Etsu Chemical Co., Ltd. (JP) | 2007-10-24 | — | — | EP | claimed |
| US-20220211725-A1 | Pharmaceutical Composition Comprising Venetoclax | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2022-07-07 | — | — | US | disclosed |
| US-11292793-B2 | Solid dispersions of amorphous Lumateperone p-Tosylate | DR. REDDY'S LABORATORIES LIMITED (IN) | 2022-04-05 | — | — | US | disclosed |
| US-20210290541-A1 | SOLID DISPERSION OF HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-09-23 | — | — | US | disclosed |
| EP-3831381-A1 | SOLID DISPERSION OF HYDANTOIN DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020225738-A1 | PHARMACEUTICAL COMPOSITION COMPRISING VENETOCLAX | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2020-11-12 | — | — | WO | disclosed |
| US-20080038340-A1 | Solid dosage form of enteric solid dispersion and method for producing the same | SHIN-ETSU CHEMICAL CO., LTD. | 2008-02-14 | — | — | US | disclosed |
| EP-1886673-A2 | Solid dosage form of enteric solid dispersion and method for producing the same | Shin-Etsu Chemical Co., Ltd. (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20070248682-A1 | SOLID PREPARATION COMPRISING ENTERIC SOLID DISPERSION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1847257-A2 | Solid preparation comprising enteric solid dispersion | Shin-Etsu Chemical Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070196399-A1 | ENTERIC-COATED PREPARATION COVERED WITH ENTERIC COATING MATERIAL FOR SITE-SPECIFIC DELIVERY OF DRUG TO SITE WITHIN THE SMALL INTESTINE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1820498-A2 | Enteric-coated preparation for site-specific delivery of drug to site within the small intestine | Shin-Etsu Chemical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292793-B2 | Solid dispersions of amorphous Lumateperone p-Tosylate | HTR2A, HTR2C, HTR1A | MEN1 3974/4885KMT2A 2047/4885USP2 1161/4885 |
| US-20210290541-A1 | SOLID DISPERSION OF HYDANTOIN DERIVATIVE | ABCG2, SEPTIN7, H1-0 | MEN1 3062/4885KMT2A 777/4885USP2 2995/4885 |
| US-20220211725-A1 | Pharmaceutical Composition Comprising Venetoclax | U2AF1, SF3B1, SF3B3 | MEN1 2388/4885KMT2A 525/4885USP2 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.